Jun X. Guo
Expertise in
21
conditions

Jun X. Guo

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Expertise in
21
conditions
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 

Overview

Jun Guo practices practicing medicine in Beijing, China.

Guo is highly rated in 21 conditions, according to our data. Their clinical expertise encompasses Melanoma, Premature Ejaculation, Renal Cell Carcinoma (RCC), Percutaneous Coronary Intervention (PCI), and Angioplasty.

They are actively involved in clinical research, co-authoring 735 peer reviewed articles and participating in 12 clinical trials.

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China
Other Locations
6 Fucheng Road, Haidian, 100048, China
28 Fuxing Road, Haidian, 100853, China
No. 789 Suzhou East Street, Ueruemqi, 830011, China
No. 16, South Renmin Road, China P.R, Chengdu, 610041, China
52 Fucheng Road, Beijing, 100142, China
No. 10 Xitucheng Road, Beijing, 100876, China
No. 52, Fucheng Road, Beijing, 100142, China
No. 8 East Street, Fengtai, 100071, China
No.10 Xitucheng Road, Haidian, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KL340399 Injection in Patients With Advanced Solid Tumors
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of KL340399 Injection in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: May 08, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)
A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: November 28, 2025
Intervention Type: Combination product, Drug
Study Drug: Axitinib
Study Phase: Phase 3
A Phase I, Single and Multiple Dose Escalation/Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Food Effect, and Preliminary Antitumor Activities of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
A Phase I, Single and Multiple Dose Escalation/Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Food Effect, and Preliminary Antitumor Activities of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drugs: TQB2450, Anlotinib, Sunitinib
Study Phase: Phase 3
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drugs: JS001, Dacarbazine
Study Phase: Phase 3
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: RC48-ADC
Study Phase: Phase 2
A Phase I/II, Single Arm, Dose Escalation and Cohort Expansion Study to Evaluate Safety, Preliminary Efficacy of HL-085 in Patients With NRAS Mutant Advanced Melanoma
A Phase I/II, Single Arm, Dose Escalation and Cohort Expansion Study to Evaluate Safety, Preliminary Efficacy of HL-085 in Patients With NRAS Mutant Advanced Melanoma
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: HL-085
Study Phase: Phase 1/Phase 2
A Single-arm, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of HL-085 in Advanced Melanoma Patients With NRAS Mutation
A Single-arm, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of HL-085 in Advanced Melanoma Patients With NRAS Mutation
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: HL-085
Study Phase: Phase 2
Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study
Evaluation of Safety, Tolerability, and Pharmacokinetics of KD6001 in Patients With Advanced Solid Tumours - Phase I Clinical Study
Enrollment Status: Completed
Publish Date: February 06, 2023
Intervention Type: Biological
Study Phase: Phase 1
A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure
A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure
Enrollment Status: Unknown
Publish Date: September 30, 2020
Intervention Type: Biological
Study Drug: Humanized Anti-PD-1 Monoclonal Antibody Toripalimab
Study Phase: Phase 2
View 9 Less Clinical Trials

733 Total Publications

Usefulness of metabolic score for insulin resistance to predict restenosis after coronary stent implantation.
Usefulness of metabolic score for insulin resistance to predict restenosis after coronary stent implantation.
Journal: Annals of medicine
Published: June 09, 2026

Frequently Asked Questions about Jun X. Guo

Is Jun X. Guo a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Jun X. Guo is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jun X. Guo participate in research or clinical trials?

Yes. Jun X. Guo has published 733 articles and abstracts on conditions like Melanoma. You can view a list of Jun X. Guo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Guo's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 97 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile